Key result
Perioperative beta-blocker use in noncardiac surgery was associated with higher rates of 30-day mortality (2.52% vs 0.25%, P=.007) and 30-day myocardial infarction (2.94% vs 0.74%, P=.03).
Why the study?
Does perioperative beta-blocker use affect perioperative cardiovascular outcomes in patients undergoing noncardiac surgery?
Population
Patients who underwent various noncardiac surgical procedures in 2000 at the Michael E. DeBakey Veterans…
Comparison
Perioperative beta-blockers vs Matched control group from the same patient…
Design
Cohort
Follow-up
1 year
Authors
Loading...
Caution advised with perioperative beta-blockers in noncardiac surgery; leaves open need for randomized confirmation.
Cohort
No
Does perioperative beta-blocker use affect perioperative cardiovascular outcomes in patients undergoing noncardiac surgery?
Absolute Event Rate: 2.52% vs 0.25%
p-value: p=.007
Perioperative beta-blocker use in noncardiac surgery was associated with increased 30-day myocardial infarction and mortality, suggesting that administration requires careful monitoring and adequate heart rate control, particularly in patients not at high cardiac risk.
Haytham M.A. Kaafarani (2008) conducted a cohort in Noncardiac surgery. Perioperative beta-blockers vs. Matched control group was evaluated on 30-day mortality (p=.007). Perioperative beta-blocker use in noncardiac surgery was associated with higher rates of 30-day mortality (2.52% vs 0.25%, P=.007) and 30-day myocardial infarction (2.94% vs 0.74%, P=.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: